middle.news
How PolyNovo’s NovoSorb BTM Is Revolutionizing Type 1 Diabetes Cell Therapy
2:39am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
How PolyNovo’s NovoSorb BTM Is Revolutionizing Type 1 Diabetes Cell Therapy
2:39am on Monday 2nd of June, 2025 AEST
Key Points
First-in-human trial shows 3-year survival of transplanted islet cells using NovoSorb BTM
NovoSorb creates a vascularised skin site allowing cell monitoring and topical immunosuppression
Trial participants with longstanding Type 1 diabetes showed improved glycaemic control
NovoSorb’s cell delivery platform could open a new business segment beyond wound care
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Polynovo (ASX:PNV)
OPEN ARTICLE